Tags

Type your tag names separated by a space and hit enter

Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management.
Ann Pharmacother. 2017 May; 51(5):401-409.AP

Abstract

OBJECTIVE

To review the pharmacology, pharmacokinetics, efficacy, and safety of the glucagon-like peptide-1 receptor agonist (GLP-1RA), lixisenatide, in the treatment of type 2 diabetes mellitus.

DATA SOURCES

A PubMed (1966-2016) search was conducted using the following keywords: lixisenatide, AVE0010, glucagon-like peptide-1 agonist, and type 2 diabetes. References were reviewed to identify additional sources.

STUDY SELECTION AND DATA EXTRACTION

Articles written in English were included if they evaluated the pharmacology, pharmacokinetics, efficacy, or safety of lixisenatide in human subjects.

DATA SYNTHESIS

Lixisenatide lowers blood glucose through a glucose-dependent increase in insulin release from pancreatic β-cells and a decreased release of glucagon from pancreatic α-cells. Additionally, lixisenatide delays gastric emptying and increases satiety. Lixisenatide has been studied head to head against exenatide and insulin glulisine. It has also been studied as monotherapy and in combination with metformin, sulfonylureas, pioglitazone, and insulin glargine. In the GetGoal clinical trial series, lixisenatide resulted in a hemoglobin A1C reduction of 0.6% to 1% and a reduction in body weight of 0.2 to 2.96 kg. The adverse effect profile of lixisenatide was consistent with that of other GLP-1RAs, with nausea, vomiting, and diarrhea most commonly reported.

CONCLUSION

Lixisenatide provides an additional GLP-1RA option, which may have more postprandial blood glucose-lowering effects than the other agents in the class because of its shorter half-life and effects on delaying gastric emptying.

Authors+Show Affiliations

1 Wingate University School of Pharmacy, Wingate, NC, USA. 2 Novant Health Waxhaw Family Physicians and Sports Medicine, Waxhaw, NC, USA.1 Wingate University School of Pharmacy, Wingate, NC, USA. 3 Matthews Free Medical Clinic, Matthews, NC, USA.1 Wingate University School of Pharmacy, Wingate, NC, USA. 4 Novant Health Cotswold Medical Clinic-Arboretum, Charlotte, NC, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28133970

Citation

McCarty, Delilah, et al. "Lixisenatide: a New Daily GLP-1 Agonist for Type 2 Diabetes Management." The Annals of Pharmacotherapy, vol. 51, no. 5, 2017, pp. 401-409.
McCarty D, Coleman M, Boland CL. Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management. Ann Pharmacother. 2017;51(5):401-409.
McCarty, D., Coleman, M., & Boland, C. L. (2017). Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management. The Annals of Pharmacotherapy, 51(5), 401-409. https://doi.org/10.1177/1060028017689878
McCarty D, Coleman M, Boland CL. Lixisenatide: a New Daily GLP-1 Agonist for Type 2 Diabetes Management. Ann Pharmacother. 2017;51(5):401-409. PubMed PMID: 28133970.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management. AU - McCarty,Delilah, AU - Coleman,Megan, AU - Boland,Cassie L, Y1 - 2017/01/29/ PY - 2017/1/31/pubmed PY - 2017/8/15/medline PY - 2017/1/31/entrez KW - glucagon-like peptide-1 receptor agonist KW - lixisenatide KW - type 2 diabetes SP - 401 EP - 409 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 51 IS - 5 N2 - OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of the glucagon-like peptide-1 receptor agonist (GLP-1RA), lixisenatide, in the treatment of type 2 diabetes mellitus. DATA SOURCES: A PubMed (1966-2016) search was conducted using the following keywords: lixisenatide, AVE0010, glucagon-like peptide-1 agonist, and type 2 diabetes. References were reviewed to identify additional sources. STUDY SELECTION AND DATA EXTRACTION: Articles written in English were included if they evaluated the pharmacology, pharmacokinetics, efficacy, or safety of lixisenatide in human subjects. DATA SYNTHESIS: Lixisenatide lowers blood glucose through a glucose-dependent increase in insulin release from pancreatic β-cells and a decreased release of glucagon from pancreatic α-cells. Additionally, lixisenatide delays gastric emptying and increases satiety. Lixisenatide has been studied head to head against exenatide and insulin glulisine. It has also been studied as monotherapy and in combination with metformin, sulfonylureas, pioglitazone, and insulin glargine. In the GetGoal clinical trial series, lixisenatide resulted in a hemoglobin A1C reduction of 0.6% to 1% and a reduction in body weight of 0.2 to 2.96 kg. The adverse effect profile of lixisenatide was consistent with that of other GLP-1RAs, with nausea, vomiting, and diarrhea most commonly reported. CONCLUSION: Lixisenatide provides an additional GLP-1RA option, which may have more postprandial blood glucose-lowering effects than the other agents in the class because of its shorter half-life and effects on delaying gastric emptying. SN - 1542-6270 UR - https://www.unboundmedicine.com/medline/citation/28133970/Lixisenatide:_A_New_Daily_GLP_1_Agonist_for_Type_2_Diabetes_Management_ L2 - http://journals.sagepub.com/doi/full/10.1177/1060028017689878?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -